Clinical trial ORIENT-15
A Multicenter, Double-blind, Randomised Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-line Treatment of Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
| Cancers | |
|---|---|
| Organ | Esophagus |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Innovent Biologics (Suzhou) Co., Ltd. |
| EudraCT Identifier | 2020-000533-40 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03748134 |
| Last update |